Home » Healthcare » Switzerland Diabetes Care Devices Market

Switzerland Diabetes Care Devices Market By Type (Monitoring, Delivery); By Monitoring Devices (Continuous Monitoring Devices, Lancets, Test Strips, Self-Monitoring Devices); By Delivery Devices (Insulin Pumps, Pens, Syringes, Needles); By End-Users (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Indication (Diabetes Type I, Diabetes Type II, Gestational Diabetes) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Switzerland Diabetes Care Devices Market Size 2023	USD 174.91 million
Switzerland Diabetes Care Devices Market, CAGR	6.67%
Switzerland Diabetes Care Devices Market Size 2032	USD 323.44 million

Market Overview

The Switzerland Diabetes Care Devices Market is expected to grow from USD 174.91 million in 2023 to USD 323.44 million by 2032, at a CAGR of 6.67%.

The Switzerland diabetes care devices market is driven by the rising prevalence of diabetes, increased awareness about early diagnosis, and the growing adoption of advanced healthcare technologies. The demand for insulin pumps, continuous glucose monitoring (CGM) systems, and smart diabetes management solutions is on the rise, as patients seek more efficient and personalized treatment options. Technological advancements, such as wearable devices that provide real-time glucose monitoring and automated insulin delivery, are enhancing treatment outcomes and improving patient convenience. Additionally, the expanding geriatric population and the shift towards home-based care further fuel market growth. Rising healthcare investments and favorable reimbursement policies also contribute to the market’s expansion. Trends show a growing focus on digital health solutions, including mobile apps and data-driven insights, to support better disease management.

The Switzerland diabetes care devices market showcases notable regional dynamics, with German-speaking Switzerland accounting for the largest share due to its advanced healthcare infrastructure, high population density, and strong adoption of innovative technologies. French-speaking Switzerland follows as the second-largest contributor, supported by a well-developed healthcare system and increasing awareness of diabetes management. Key players driving the market include Abbott Laboratories, Ascensia Diabetes Care Holdings AG, F. Hoffmann-La Roche Ltd, Medtronic plc, and Dexcom, Inc., among others. These companies lead with advanced product offerings, including continuous glucose monitoring systems, insulin pumps, and self-monitoring devices. Collaborations between local healthcare providers and global manufacturers foster the adoption of cutting-edge solutions. Additionally, supportive government policies and rising healthcare expenditure further boost market growth across regions, ensuring the availability of innovative and effective diabetes care devices to meet the growing patient demand.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The Switzerland diabetes care devices market is projected to grow from USD 174.91 million in 2023 to USD 323.44 million by 2032, with a CAGR of 6.67%.
Rising diabetes prevalence, driven by aging populations and lifestyle factors, is significantly increasing demand for advanced monitoring and treatment solutions.
Continuous advancements in technology, including CGM systems and smart insulin pumps, are enhancing accuracy and convenience, driving market growth.
High costs of devices and consumables remain a key restraint, limiting accessibility for some patients despite strong healthcare infrastructure.
German-speaking Switzerland dominates the market due to its robust healthcare facilities and higher adoption of innovative technologies.
French-speaking Switzerland contributes significantly, supported by a focus on diabetes awareness and proactive management initiatives.
Leading companies such as Abbott Laboratories, Medtronic plc, and F. Hoffmann-La Roche Ltd are driving innovation, ensuring the availability of advanced solutions across the region.

Market Drivers

Emphasis on Early Detection and Proactive Management

A strong focus on early detection and proactive management of diabetes is further accelerating the adoption of diabetes care devices in Switzerland. Early detection can help prevent severe complications such as heart disease, kidney failure, and neuropathy, while proactive management leads to better quality of life for patients. For instance, the Swiss Diabetes Association emphasizes the importance of early detection and regular monitoring to manage diabetes effectively. The increasing awareness of the benefits of early intervention is pushing both healthcare professionals and patients to turn to advanced devices such as continuous glucose monitoring (CGM) systems and insulin pumps, which enable consistent and real-time monitoring of blood glucose levels.

Technological Advancements

Continuous advancements in diabetes care technology are driving market growth. Devices like CGM systems, insulin pumps, and smart diabetes management tools are becoming more popular due to their ability to offer improved accuracy, convenience, and personalized treatment options. These technological innovations are enhancing the effectiveness of diabetes management, offering patients better control over their condition. For instance, the Medtronic MiniMed 780G insulin pump, which includes advanced features for automated insulin delivery, has been well-received in Switzerland. The introduction of wearable devices, mobile health apps, and automated insulin delivery systems are enabling more seamless integration of diabetes care into daily life, making management easier and more effective for patients.

Government Initiatives and Reimbursement Policies

Supportive government initiatives and favorable reimbursement policies also play a key role in the growth of the diabetes care devices market in Switzerland. The country’s robust healthcare system, which emphasizes patient well-being, creates a positive environment for the adoption of advanced healthcare solutions. For instance, the Federal Council’s Health2030 strategy includes measures to improve the management of chronic diseases like diabetes. With favorable reimbursement schemes in place, healthcare providers and patients are more likely to invest in advanced diabetes care devices. Furthermore, Switzerland’s growing healthcare expenditure allows for continued investment in the latest technology, making diabetes care more accessible and efficient.

Rising Prevalence of Diabetes

The increasing prevalence of diabetes, particularly type 2 diabetes, is a significant driver for the growth of diabetes care devices in Switzerland. Factors such as aging populations, sedentary lifestyles, and unhealthy dietary habits have led to a rise in diabetes cases. In Switzerland, as in many developed nations, a large portion of the population is affected by diabetes, creating substantial demand for effective management tools. As the incidence of diabetes continues to grow, the need for devices that aid in monitoring and controlling blood sugar levels becomes even more critical.

Market Trends

Rising Prevalence of Diabetes and Focus on Early Detection

The rising prevalence of both Type 1 and Type 2 diabetes is a significant driver for the demand for advanced diabetes care devices in Switzerland. Factors like an aging population, sedentary lifestyles, and unhealthy diets contribute to the increasing incidence of diabetes. This trend is particularly evident among older adults, who are at higher risk of developing diabetes and related complications. As the number of diabetes cases continues to rise, the need for effective monitoring and treatment devices is becoming more urgent. For instance, the Swiss Diabetes Association emphasizes the importance of early detection and regular monitoring to manage diabetes effectively. Additionally, there is a growing emphasis on early detection and proactive management of diabetes. Early detection of blood sugar abnormalities, such as hypoglycemia and hyperglycemia, is crucial for preventing severe complications like heart disease, kidney failure, and nerve damage. Diabetes care devices, especially continuous glucose monitoring (CGM) systems, enable real-time tracking, allowing patients and healthcare providers to take timely action and make informed decisions to optimize diabetes management and prevent complications.

Technological Advancements and Patient Empowerment

Technological advancements are transforming diabetes care, leading to more accurate, user-friendly, and integrated solutions. Continuous innovations in diabetes care devices, such as CGM systems, insulin pumps, and smart devices, are significantly improving patient outcomes. These devices are designed to offer better precision and convenience, providing patients with real-time data on their blood glucose levels and making it easier to manage their condition. The integration of artificial intelligence (AI) and machine learning into these devices is expected to further enhance their capabilities by offering more personalized treatment plans and predictive insights. Furthermore, there is a growing focus on patient empowerment and self-management. Advanced diabetes care devices, including smartphone-connected glucose meters and insulin pumps, enable patients to take control of their diabetes care. These devices not only allow individuals to monitor their blood glucose levels but also facilitate insulin administration and decision-making, promoting independence and improving overall quality of life. The combination of technological advancements and a shift towards patient empowerment is revolutionizing diabetes care, making it more accessible, efficient, and personalized for individuals in Switzerland.

Market Challenges Analysis

High Costs and Reimbursement Hurdles

The high cost of diabetes care devices and consumables presents a significant barrier to widespread adoption in Switzerland. Advanced devices such as continuous glucose monitors (CGM) and insulin pumps can be prohibitively expensive, making them inaccessible to some patients, particularly those without sufficient insurance coverage. For instance, the average cost of diabetes treatment per patient in Switzerland is approximately CHF 3,500 annually. Additionally, the ongoing cost of consumables, such as test strips, lancets, and CGM sensors, can add a substantial financial burden for patients who require multiple daily tests. These costs can deter patients from fully embracing advanced diabetes management tools, potentially limiting the effectiveness of their treatment. Another major challenge is navigating the complex reimbursement landscape in Switzerland. While the country boasts a strong healthcare system, reimbursement coverage for certain devices and supplies can be limited or require extensive paperwork. This creates additional hurdles for both healthcare providers and patients, slowing the adoption of advanced diabetes care devices and increasing the financial burden on those who need them the most.

Device Complexity, Adherence, and Regulatory Hurdles

Patient adherence to diabetes care plans can be significantly impacted by the complexity of some advanced devices, including insulin pumps and CGM systems. These devices often require substantial training for effective use, which can be a barrier for patients, especially those with cognitive impairments or younger patients who may struggle with the complexity of these tools. Ensuring that patients consistently use their devices and follow prescribed treatment plans is crucial for achieving optimal diabetes management outcomes. Furthermore, concerns about data privacy and cybersecurity add another layer of complexity to the market. As diabetes care devices become increasingly connected to digital platforms, the sharing of sensitive health data with healthcare providers and manufacturers raises concerns about data privacy and security. The risk of cyberattacks and data breaches also increases as more devices rely on internet connectivity. Finally, the strict regulatory environment in Switzerland, while ensuring product safety, can increase the time and cost involved in bringing new devices to market. Changes in regulatory guidelines can further complicate this process, particularly for emerging technologies, posing additional challenges for manufacturers and healthcare providers alike.

Market Opportunities

Expanding Adoption of Smart Diabetes Devices

One of the key market opportunities in Switzerland’s diabetes care device sector lies in the growing adoption of smart devices and connected health technologies. As patients increasingly seek more efficient and personalized diabetes management tools, the demand for advanced solutions such as continuous glucose monitoring (CGM) systems, insulin pumps, and smartphone-integrated devices is set to rise. These devices offer significant benefits, including real-time data monitoring, automated insulin delivery, and enhanced patient engagement. With the increasing prevalence of diabetes and a focus on early detection and proactive management, the market is primed for expansion. The integration of artificial intelligence (AI) and machine learning into these devices further enhances their value, providing patients with personalized treatment plans and predictive insights. Manufacturers can capitalize on this trend by focusing on innovations that improve device accuracy, ease of use, and overall patient experience.

Government Support and Healthcare Investments

Switzerland’s robust healthcare system and supportive government policies present another opportunity for growth in the diabetes care device market. With a strong emphasis on patient well-being and improving healthcare accessibility, Switzerland provides an attractive environment for the adoption of advanced diabetes care solutions. Rising healthcare expenditure allows for greater investments in innovative medical devices and therapies, including diabetes management tools. Furthermore, government initiatives aimed at improving diabetes care and prevention, coupled with favorable reimbursement policies for medical devices, offer a positive regulatory landscape for manufacturers. By aligning with these opportunities, companies can expand their market presence and contribute to improving diabetes care outcomes for a growing patient population.

Market Segmentation Analysis:

By Type:

The Switzerland diabetes care devices market can be broadly segmented into two categories: monitoring devices and delivery devices. Monitoring devices play a crucial role in the management of diabetes by providing real-time insights into blood glucose levels, enabling patients to make timely adjustments to their treatment plans. Within the monitoring devices segment, continuous glucose monitoring (CGM) systems are increasingly popular due to their ability to offer real-time data and reduce the need for frequent finger-stick testing. Self-monitoring devices, such as glucometers, continue to be widely used for their convenience and cost-effectiveness. Additionally, consumables like lancets and test strips remain essential for diabetes monitoring, even with the rise of more advanced solutions. Despite the shift toward continuous monitoring, traditional devices still account for a significant portion of the market, particularly for patients who require frequent testing or have budgetary constraints.

By Monitoring Devices:

Continuous monitoring devices, particularly Continuous Glucose Monitoring (CGM) systems, represent a significant segment of the Switzerland diabetes care devices market. These devices offer real-time monitoring of blood glucose levels, allowing patients to make informed decisions about their insulin intake and lifestyle adjustments. Other important segments of the market include test strips, lancets, and self-monitoring devices. Despite the growing adoption of CGMs, test strips and lancets remain essential for many diabetes patients, particularly those who prefer traditional monitoring methods or have financial constraints. These devices are often used in conjunction with self-monitoring glucose meters, providing patients with a simple and affordable means of tracking blood glucose levels at home. The demand for these devices remains steady due to their affordability and ease of use. However, the shift towards more advanced and automated systems is gradually affecting the growth rate of these traditional monitoring tools. Manufacturers in this segment continue to innovate by offering more cost-effective, high-quality strips and lancets to meet the needs of patients who rely on these devices for day-to-day diabetes management.

Segments:

Based on Type:

Monitoring
Delivery

Based on Monitoring Devices:

Continuous Monitoring Devices
Lancets
Test Strips
Self Monitoring Devices

Based on Delivery Devices:

Insulin Pumps
Pens
Syringes
Needles

Based on End-Users:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Based on Indication:

Diabetes Type I
Diabetes Type II
Gestational Diabetes

Based on the Geography:

German-speaking Switzerland
French-speaking Switzerland

Regional Analysis

German-speaking Switzerland

German-speaking Switzerland holds the largest share of the diabetes care devices market, accounting for approximately 60% of the national revenue. This region’s dominance can be attributed to its high population density, advanced healthcare infrastructure, and significant adoption of innovative technologies. Cities like Zurich, Basel, and Bern are home to world-class healthcare facilities and research centers that actively promote advanced diabetes care solutions, including continuous glucose monitoring (CGM) systems and insulin pumps. The increasing prevalence of diabetes in this region, driven by aging demographics and lifestyle-related factors, has led to a heightened demand for effective monitoring and treatment tools. Furthermore, government initiatives supporting early detection and proactive management of diabetes have further fueled market growth. The region’s strong economic base allows for higher healthcare expenditure, making premium diabetes care devices more accessible. Additionally, widespread awareness programs and patient education initiatives contribute to the robust adoption of advanced diabetes management solutions in German-speaking Switzerland.

French-Speaking Switzerland

French-speaking Switzerland represents approximately 30% of the Switzerland diabetes care devices market, making it the second-largest regional contributor. This region, encompassing cities such as Geneva, Lausanne, and Neuchâtel, benefits from a well-developed healthcare system and a strong focus on patient well-being. The adoption of diabetes care devices in this region is driven by growing awareness of diabetes complications and the benefits of advanced monitoring solutions. Continuous glucose monitoring (CGM) systems and self-monitoring devices are increasingly popular among the population, particularly for managing Type 1 diabetes. The presence of international healthcare organizations and collaborations with global medical device manufacturers also facilitate the introduction of cutting-edge technologies. However, challenges such as relatively lower population density compared to German-speaking regions and varying levels of device affordability can slightly limit growth. Despite these challenges, ongoing investments in healthcare infrastructure and favorable government policies are expected to drive steady market expansion in French-speaking Switzerland.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Abbott Laboratories
ACON Laboratories, Inc.
Ascensia Diabetes Care Holdings AG
Becton, Dickinson and Company
Dexcom, Inc.
Hoffmann-La Roche Ltd
Johnson & Johnson
Medtronic plc
Novo Nordisk A/S
Ascensia Diabetes Care
Company 11
Company 12
Company 13
Company 14

Competitive Analysis

The Switzerland diabetes care devices market is characterized by strong competition among global and regional players, with key companies such as Abbott Laboratories, Ascensia Diabetes Care Holdings AG, F. Hoffmann-La Roche Ltd, Medtronic plc, and Dexcom, Inc. driving innovation. These companies focus on developing advanced solutions like continuous glucose monitoring (CGM) systems, insulin pumps, and self-monitoring devices to address the growing demand for effective diabetes management tools. Leading companies prioritize developing cutting-edge technologies, including continuous glucose monitoring (CGM) systems, insulin pumps, and self-monitoring devices, to meet the growing demand for effective diabetes care. These innovations aim to enhance accuracy, convenience, and patient outcomes. Firms operating in this market employ strategies such as product differentiation, research and development investments, and strategic collaborations to strengthen their market presence. Additionally, partnerships with healthcare providers and technological integration, such as smartphone connectivity and artificial intelligence, have emerged as key competitive strategies. The Swiss market’s robust healthcare infrastructure and patient-centric approach provide a fertile ground for market players to expand their footprint. As diabetes prevalence rises and technology evolves, competition is expected to intensify, driving further advancements and improving the accessibility of innovative diabetes care devices.

Recent Developments

In October 2024, Glooko secured a USD 100 million investment aimed at expanding its diabetes management system. The funding was intended to enhance the company’s reach across North America, as well as the Middle East and Asia.
In August 2024, Medtronic announced its partnership with Abbott, which was expected to improve its struggling diabetes care segment by integrating advanced glucose monitoring technology, enhancing their offerings and potentially strengthening Medtronic’s position in the market.
In March 2024, Dexcom introduced its newest CGM system, Dexcom ONE+, in Ireland. Dexcom ONE+ utilizes Dexcom’s top-tier and highly accurate sensor design. This product launch will bolster the company’s product portfolio in the Irish market and is expected to boost the company’s revenue.
In May 2023, Medtronic agreed to acquire EOFlow, a manufacturer of insulin devices. The integration of EOFlow with Medtronic’s Meal Detection Technology algorithm and advanced continuous glucose monitor (CGM) is expected to enhance the company’s ability to serve a broader range of people with diabetes
In April 2023, Undbio announced its plan to invest USD 100 million in constructing a US-based insulin manufacturing plant. The South Korean company intends to build a new facility in West Virginia to manufacture insulin and distribute its products within the country
In July 2023, CharmHealth and Bioverge jointly invested in My Diabetes Tutor, a startup focused on improving the lives of individuals with diabetes

Market Concentration & Characteristics

The Switzerland diabetes care devices market is moderately concentrated, with a mix of global leaders and regional players dominating the landscape. Established multinational companies hold significant market shares due to their advanced technologies, extensive product portfolios, and strong distribution networks. These players drive innovation in diabetes management, offering cutting-edge solutions such as continuous glucose monitoring (CGM) systems, smart insulin pumps, and integrated self-monitoring devices. However, regional players contribute to market diversity by providing cost-effective and localized solutions that cater to specific patient needs.

The market is characterized by a high level of technological integration, with advancements such as smartphone connectivity, artificial intelligence (AI), and predictive analytics reshaping diabetes care. Switzerland’s robust healthcare infrastructure and patient-centric policies create an environment conducive to the adoption of these advanced devices. Despite the market’s strong foundation, challenges such as high device costs and stringent regulatory requirements add complexity to the competitive dynamics. Companies continuously focus on research and development, strategic partnerships, and market expansion to maintain their competitive edge. As diabetes prevalence grows and patient awareness increases, the market’s competitive structure is expected to foster innovation, ensuring improved accessibility and enhanced outcomes for diabetes care in Switzerland.

Report Coverage

The research report offers an in-depth analysis based on Type, Monitoring Devices, Delivery Devices, Indication, End-Users and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Switzerland diabetes care devices market is expected to experience sustained growth driven by rising diabetes prevalence and aging demographics.
Technological advancements in continuous glucose monitoring systems and insulin pumps will enhance accuracy and patient convenience.
Increased integration of artificial intelligence and machine learning will enable more personalized diabetes management solutions.
Smartphone connectivity and app-based platforms will play a key role in empowering patients to monitor and manage their conditions effectively.
Expanding government initiatives and favorable reimbursement policies are likely to improve device accessibility and adoption.
Growing healthcare expenditure in Switzerland will support investments in advanced diabetes care technologies.
Emphasis on early detection and proactive management will continue to drive demand for innovative monitoring devices.
Collaboration between healthcare providers and technology developers will foster the introduction of advanced solutions in the market.
Awareness programs and educational initiatives will increase patient engagement and adherence to diabetes management plans.
Market competition will intensify, prompting companies to focus on innovation, affordability, and patient-centric solutions.

CHAPTER NO. 1 : INTRODUCTION 21

1.1.1. Report Description 21

Purpose of the Report 21

USP & Key Offerings 21

1.1.2. Key Benefits for Stakeholders 21

1.1.3. Target Audience 22

1.1.4. Report Scope 22

CHAPTER NO. 2 : EXECUTIVE SUMMARY 23

2.1. DIABETES CARE DEVICES Market Snapshot 23

2.1.1. Switzerland DIABETES CARE DEVICES Market, 2018 – 2032 (USD Million) 24

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 25

3.1. Switzerland-Ukraine and Israel-Palestine War Impacts 25

CHAPTER NO. 4 : DIABETES CARE DEVICES MARKET – INDUSTRY ANALYSIS 26

4.1. Introduction 26

4.2. Market Drivers 27

4.2.1. Rising Prevalnce of Diabetes 27

4.2.2. Unhealthy life style and habits increasing the risks of Diabetes 28

4.3. Market Restraints 29

4.3.1. Invasive technologies increasing the risk of infection 29

4.4. Market Opportunities 30

4.4.1. Market Opportunity Analysis 30

4.5. Porter’s Five Forces Analysis 31

4.6. Value Chain Analysis 32

4.7. Buying Criteria 33

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 34

5.1. Import Analysis by Switzerland 34

5.1.1. Switzerland DIABETES CARE DEVICES Market Import Volume/Revenue, By Switzerland, 2018 – 2023 34

5.2. Export Analysis by Switzerland 35

5.2.1. Switzerland DIABETES CARE DEVICES Market Export Volume/Revenue, By Switzerland, 2018 – 2023 35

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 36

6.1. Demand Analysis by Switzerland 36

6.1.1. Switzerland DIABETES CARE DEVICES Market Demand Volume/Revenue, By Switzerland, 2018 – 2023 36

6.2. Supply Analysis by Switzerland 37

6.2.1. Switzerland DIABETES CARE DEVICES Market Supply Volume/Revenue, By Switzerland, 2018 – 2023 37

CHAPTER NO. 7 : PRODUCTION ANALYSIS 38

7.1. Production Analysis by Switzerland 38

7.1.1. Switzerland DIABETES CARE DEVICES Market Production Volume/Revenue, By Switzerland, 2018 – 2023 38

CHAPTER NO. 8 : PRICE ANALYSIS 39

8.1. Price Analysis by Type 39

8.1.1. Switzerland DIABETES CARE DEVICES Market Price, By Type, 2018 – 2023 39

8.1.2. Switzerland Type Market Price, By Type, 2018 – 2023 39

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 40

9.1. Key Raw Materials and Suppliers 40

9.2. Key Raw Materials Price Trend 40

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 41

10.1. Manufacturing Cost Analysis 41

10.2. Manufacturing Process 41

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 42

11.1. Company Market Share Analysis – 2023 42

11.1.1. Switzerland DIABETES CARE DEVICES Market: Company Market Share, by Volume, 2023 42

11.1.2. Switzerland DIABETES CARE DEVICES Market: Company Market Share, by Revenue, 2023 43

11.1.3. Switzerland DIABETES CARE DEVICES Market: Top 6 Company Market Share, by Revenue, 2023 43

11.1.4. Switzerland DIABETES CARE DEVICES Market: Top 3 Company Market Share, by Revenue, 2023 44

11.2. Switzerland DIABETES CARE DEVICES Market Company Volume Market Share, 2023 45

11.3. Switzerland DIABETES CARE DEVICES Market Company Revenue Market Share, 2023 46

11.4. Company Assessment Metrics, 2023 47

11.4.1. Stars 47

11.4.2. Emerging Leaders 47

11.4.3. Pervasive Players 47

11.4.4. Participants 47

11.5. Start-ups /SMEs Assessment Metrics, 2023 47

11.5.1. Progressive Companies 47

11.5.2. Responsive Companies 47

11.5.3. Dynamic Companies 47

11.5.4. Starting Blocks 47

11.6. Strategic Developments 48

11.6.1. Acquisitions & Mergers 48

New Product Launch 48

Switzerland Expansion 48

11.7. Key Players Product Matrix 49

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 50

12.1. PESTEL 50

12.1.1. Political Factors 50

12.1.2. Economic Factors 50

12.1.3. Social Factors 50

12.1.4. Technological Factors 50

12.1.5. Environmental Factors 50

12.1.6. Legal Factors 50

12.2. Adjacent Market Analysis 50

CHAPTER NO. 13 : DIABETES CARE DEVICES MARKET – BY TYPE SEGMENT ANALYSIS 51

13.1. DIABETES CARE DEVICES Market Overview, by Type Segment 51

13.1.1. DIABETES CARE DEVICES Market Revenue Share, By Type, 2023 & 2032 52

13.1.2. DIABETES CARE DEVICES Market Attractiveness Analysis, By Type 53

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 53

13.1.4. DIABETES CARE DEVICES Market Revenue, By Type, 2018, 2023, 2027 & 2032 54

13.2. Monitoring 55

13.3. Delivery 56

CHAPTER NO. 14 : DIABETES CARE DEVICES MARKET – BY MONITORING DEVICES SEGMENT ANALYSIS 57

14.1. DIABETES CARE DEVICES Market Overview, by Monitoring Devices Segment 57

14.1.1. DIABETES CARE DEVICES Market Revenue Share, By Monitoring Devices , 2023 & 2032 58

14.1.2. DIABETES CARE DEVICES Market Attractiveness Analysis, By Monitoring Devices 59

14.1.3. Incremental Revenue Growth Opportunity, by Monitoring Devices , 2024 – 2032 59

14.1.4. DIABETES CARE DEVICES Market Revenue, By Monitoring Devices , 2018, 2023, 2027 & 2032 60

14.2. Continuous Monitoring Devices 61

14.3. Lancets 62

14.4. Test Strips 63

14.5. Self Monitoring Devices 64

CHAPTER NO. 15 : DIABETES CARE DEVICES MARKET – BY DELIVERY DEVICES SEGMENT ANALYSIS 65

15.1. DIABETES CARE DEVICES Market Overview, by Delivery Devices Segment 65

15.1.1. DIABETES CARE DEVICES Market Revenue Share, By Delivery Devices , 2023 & 2032 66

15.1.2. DIABETES CARE DEVICES Market Attractiveness Analysis, By Delivery Devices 67

15.1.3. Incremental Revenue Growth Opportunity, by Delivery Devices , 2024 – 2032 67

15.1.4. DIABETES CARE DEVICES Market Revenue, By Delivery Devices , 2018, 2023, 2027 & 2032 68

15.2. Insulin Pumps 69

15.3. Pens 70

15.4. Syringes 71

15.5. Needles 72

CHAPTER NO. 16 : DIABETES CARE DEVICES MARKET – BY END-USERS SEGMENT ANALYSIS 73

16.1. DIABETES CARE DEVICES Market Overview, by End-Users Segment 73

16.1.1. DIABETES CARE DEVICES Market Revenue Share, By End-Users, 2023 & 2032 74

16.1.2. DIABETES CARE DEVICES Market Attractiveness Analysis, By End-Users 75

16.1.3. Incremental Revenue Growth Opportunity, by End-Users, 2024 – 2032 75

16.1.4. DIABETES CARE DEVICES Market Revenue, By End-Users, 2018, 2023, 2027 & 2032 76

16.2. Hospital Pharmacies 77

16.3. Retail Pharmacies 78

16.4. Online Pharmacies 79

CHAPTER NO. 17 : DIABETES CARE DEVICES MARKET – BY INDICATION CHANNEL SEGMENT ANALYSIS 80

17.1. DIABETES CARE DEVICES Market Overview, by Indication Channel Segment 80

17.1.1. DIABETES CARE DEVICES Market Revenue Share, By Indication Channel, 2023 & 2032 81

17.1.2. DIABETES CARE DEVICES Market Attractiveness Analysis, By Indication Channel 82

17.1.3. Incremental Revenue Growth Opportunity, by Indication Channel, 2024 – 2032 82

17.1.4. DIABETES CARE DEVICES Market Revenue, By Indication Channel, 2018, 2023, 2027 & 2032 83

17.2. Diabetes Type I 84

17.3. Diabetes Type II 85

17.4. Gestational Diabetes 86

CHAPTER NO. 18 : DIABETES CARE DEVICES MARKET – SWITZERLAND ANALYSIS 87

18.1. Type 87

18.1.1. Switzerland DIABETES CARE DEVICES Market Revenue, By Type, 2018 – 2023 (USD Million) 87

18.2. Switzerland DIABETES CARE DEVICES Market Revenue, By Type, 2024 – 2032 (USD Million) 87

18.3. Monitoring Devices 88

18.3.1. Switzerland DIABETES CARE DEVICES Market Revenue, By Monitoring Devices , 2018 – 2023 (USD Million) 88

18.3.2. Switzerland DIABETES CARE DEVICES Market Revenue, By Monitoring Devices , 2024 – 2032 (USD Million) 88

18.4. Delivery Devices 89

18.4.1. Switzerland DIABETES CARE DEVICES Market Revenue, By Delivery Devices , 2018 – 2023 (USD Million) 89

18.4.2. Switzerland DIABETES CARE DEVICES Market Revenue, By Delivery Devices , 2024 – 2032 (USD Million) 89

18.5. End-Users 90

18.5.1. Switzerland DIABETES CARE DEVICES Market Revenue, By End-Users, 2018 – 2023 (USD Million) 90

18.5.2. Switzerland DIABETES CARE DEVICES Market Revenue, By End-Users, 2024 – 2032 (USD Million) 90

18.6. Indication Channel 91

18.6.1. Switzerland DIABETES CARE DEVICES Market Revenue, By Indication Channel, 2018 – 2023 (USD Million) 91

18.6.2. Switzerland DIABETES CARE DEVICES Market Revenue, By Indication Channel, 2024 – 2032 (USD Million) 91

CHAPTER NO. 19 : COMPANY PROFILES 92

19.1. Abbott Laboratories 92

19.1.1. Company Overview 92

19.1.2. Product Portfolio 92

19.1.3. Swot Analysis 92

19.1.4. Business Strategy 93

19.1.5. Financial Overview 93

19.2. ACON Laboratories, Inc. 94

19.3. Ascensia Diabetes Care Holdings AG 94

19.4. Becton, Dickinson and Company 94

19.5. Dexcom, Inc. 94

19.6. F. Hoffmann-La Roche Ltd 94

19.7. Johnson & Johnson 94

19.8. Medtronic plc 94

19.9. Novo Nordisk A/S 94

19.10. ASCENSIA DIABETES CARE 94

19.11. Company 11 94

19.12. Company 12 94

19.13. Company 13 94

19.14. Company 14 94

List of Figures

FIG NO. 1. Switzerland DIABETES CARE DEVICES Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Switzerland DIABETES CARE DEVICES Market 29

FIG NO. 3. Value Chain Analysis for Switzerland DIABETES CARE DEVICES Market 30

FIG NO. 4. Switzerland DIABETES CARE DEVICES Market Import Volume/Revenue, By Switzerland, 2018 – 2023 32

FIG NO. 5. Switzerland DIABETES CARE DEVICES Market Export Volume/Revenue, By Switzerland, 2018 – 2023 33

FIG NO. 6. Switzerland DIABETES CARE DEVICES Market Demand Volume/Revenue, By Switzerland, 2018 – 2023 34

FIG NO. 7. Switzerland DIABETES CARE DEVICES Market Supply Volume/Revenue, By Switzerland, 2018 – 2023 35

FIG NO. 8. Switzerland DIABETES CARE DEVICES Market Production Volume/Revenue, By Switzerland, 2018 – 2023 36

FIG NO. 9. Switzerland DIABETES CARE DEVICES Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. DIABETES CARE DEVICES Market – Company Volume Market Share, 2023 43

FIG NO. 18. DIABETES CARE DEVICES Market – Company Revenue Market Share, 2023 44

FIG NO. 19. DIABETES CARE DEVICES Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. DIABETES CARE DEVICES Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. Switzerland DIABETES CARE DEVICES Market for Monitoring, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. Switzerland DIABETES CARE DEVICES Market for Delivery, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. Switzerland DIABETES CARE DEVICES Market for Type 3, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. Switzerland DIABETES CARE DEVICES Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. Switzerland DIABETES CARE DEVICES Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. DIABETES CARE DEVICES Market Revenue Share, By Monitoring Devices , 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Monitoring Devices 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Monitoring Devices , 2024 – 2032 60

FIG NO. 31. DIABETES CARE DEVICES Market Revenue, By Monitoring Devices , 2018, 2023, 2027 & 2032 61

FIG NO. 32. Switzerland DIABETES CARE DEVICES Market for Continuous Monitoring Devices, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. Switzerland DIABETES CARE DEVICES Market for Lancets, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. Switzerland DIABETES CARE DEVICES Market for Test Strips, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. Switzerland DIABETES CARE DEVICES Market for Self Monitoring Devices, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. Switzerland DIABETES CARE DEVICES Market for Monitoring Devices 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. DIABETES CARE DEVICES Market Revenue Share, By Delivery Devices , 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By Delivery Devices 69

FIG NO. 39. Incremental Revenue Growth Opportunity by Delivery Devices , 2024 – 2032 69

FIG NO. 40. DIABETES CARE DEVICES Market Revenue, By Delivery Devices , 2018, 2023, 2027 & 2032 70

FIG NO. 41. Switzerland DIABETES CARE DEVICES Market for Insulin Pumps, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. Switzerland DIABETES CARE DEVICES Market for Pens, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. Switzerland DIABETES CARE DEVICES Market for Syringes, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. Switzerland DIABETES CARE DEVICES Market for Needles, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. Switzerland DIABETES CARE DEVICES Market for Delivery Devices 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. DIABETES CARE DEVICES Market Revenue Share, By End-Users, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By End-Users 78

FIG NO. 48. Incremental Revenue Growth Opportunity by End-Users, 2024 – 2032 78

FIG NO. 49. DIABETES CARE DEVICES Market Revenue, By End-Users, 2018, 2023, 2027 & 2032 79

FIG NO. 50. Switzerland DIABETES CARE DEVICES Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. Switzerland DIABETES CARE DEVICES Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. Switzerland DIABETES CARE DEVICES Market for Online Pharmacies, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. DIABETES CARE DEVICES Market Revenue Share, By Indication Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Indication Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Indication Channel, 2024 – 2032 85

FIG NO. 56. DIABETES CARE DEVICES Market Revenue, By Indication Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. Switzerland DIABETES CARE DEVICES Market for Diabetes Type I, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. Switzerland DIABETES CARE DEVICES Market for Diabetes Type II, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. Switzerland DIABETES CARE DEVICES Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. Switzerland DIABETES CARE DEVICES Market for Indication Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. Switzerland DIABETES CARE DEVICES Market for Indication Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

Frequently Asked Questions

What is the current size of the Switzerland Diabetes Care Devices market?

The Switzerland diabetes care devices market is valued at USD 174.91 million in 2023 and is projected to grow to USD 323.44 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.67%.

What factors are driving the growth of the Switzerland Diabetes Care Devices market?

The market growth is driven by the rising prevalence of diabetes, technological advancements in devices like continuous glucose monitoring (CGM) systems and insulin pumps, a growing focus on early detection and proactive management, supportive government initiatives, and favorable reimbursement policies. An aging population and the shift towards home-based care also contribute significantly to market expansion.

What are the key segments within the Switzerland Diabetes Care Devices market?

The market is segmented into monitoring devices (including CGM systems, lancets, test strips, and self-monitoring devices) and delivery devices (such as insulin pumps, pens, syringes, and needles). Key end-users include hospital pharmacies, retail pharmacies, and online pharmacies. The market also addresses different indications, including Type 1 diabetes, Type 2 diabetes, and gestational diabetes.

What are some challenges faced by the Switzerland Diabetes Care Devices market?

High device costs and the ongoing expense of consumables like test strips and CGM sensors limit accessibility for some patients. Navigating complex reimbursement processes and addressing patient adherence to device usage are additional challenges. Furthermore, concerns about data privacy and cybersecurity, coupled with regulatory hurdles for new technologies, add to the complexity of the market.

Who are the major players in the Switzerland Diabetes Care Devices market?

Key players in the market include Abbott Laboratories, Ascensia Diabetes Care Holdings AG, F. Hoffmann-La Roche Ltd, Medtronic plc, and Dexcom, Inc. These companies focus on developing advanced solutions like CGM systems, insulin pumps, and smart diabetes management devices to meet the growing demand for effective diabetes care tools.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –